Active Ingredient History
Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. Modafinil is not indicated for complaints of lack of energy or fatigue; but it appears to be very helpful for some patients. Also, it has been used in the treatment of hypersomnia, a disorder in which patients lack the capacity for meaningful sleep and may require ten or more hours per day. Recent studies have have found that modafinil may help recovering cocaine addicts fight their addiction. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. Modafinil is thought to have less potential for abuse than other stimulants due to the absence of any significant euphoric or pleasurable effects. It is possible that modafinil acts by a synergistic combination of mechanisms including direct inhibition of dopamine reuptake, indirect inhibition of noradrenalin reuptake in the VLPO and orexin activation. Modafinil has partial alpha 1B-adrenergic agonist effects by directly stimulating the receptors. Modafinil is indicated for the improvement of wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Apnea (Phase 3)
Binge-Eating Disorder (Phase 3)
Brain Injuries, Traumatic (Phase 3)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Cognition Disorders (Phase 2)
Depression (Phase 3)
Depressive Disorder, Major (Phase 4)
Disorders of Excessive Somnolence (Phase 3)
Dysthymic Disorder (Phase 4)
Esophageal Neoplasms (Phase 2)
Fatigue (Phase 4)
Fibromyalgia (Phase 4)
Glioma (Phase 2)
Head and Neck Neoplasms (Phase 1/Phase 2)
Healthy Volunteers (Phase 1/Phase 2)
Hepatitis C (Phase 4)
HIV Infections (Phase 4)
Infant, Premature (Phase 3)
Lewy Body Disease (Phase 4)
Menopause (Phase 4)
Multiple Myeloma (Phase 3)
Multiple Sclerosis (Phase 2/Phase 3)
Narcolepsy ()
Neoplasms (Phase 2)
Nervous System Neoplasms (Phase 2)
Nocturia (Phase 2/Phase 3)
Obesity (Phase 3)
Overweight (Phase 3)
Paresis (Phase 2)
Psychotic Disorders (Phase 4)
Sarcoidosis (Phase 2/Phase 3)
Schizophrenia (Phase 4)
Sleep Apnea, Obstructive (Phase 4)
Sleep Apnea Syndromes (Phase 3)
Sleep Deprivation (Phase 2)
Sleep Disorders, Circadian Rhythm (Phase 3)
Sleep Disorders, Intrinsic (Phase 4)
Sleepiness (Phase 2/Phase 3)
Sleep Initiation and Maintenance Disorders (Phase 2/Phase 3)
Sleep Wake Disorders (Phase 4)
Stroke (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
